null

null

null

null

-0.02x Total Debt / Equity (Negative equity)

Minimal debt leverage; clinical-stage biotech funded by equity raises, so 20bp rate shift has negligible direct debt-service impact but raises equity dilution cost

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) API/GMP-grade chemical precursors from single-source specialty suppliers; 2) Chinese raw material inputs for carbohydrate chemistry components

No international revenue currently; pre-revenue clinical stage, so sovereign currency devaluation exposure is effectively zero

Operates solely in US; no international revenue markets, rendering currency devaluation exposure null across all geographies

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single CRO partners for GLP toxicology and synthesis; likely >30% operational input from non-substitutable specialized contract labs

Pre-revenue biotech; no cloud-dependent SaaS product, so AWS/GCP/Azure termination would affect only administrative IT, not core IP or operations

IP licensing and potential pharma partnership model; cloud infrastructure termination would cause minor disruption, recoverable within 30 days

Low API coupling risk; no externally coupled software APIs; core asset is proprietary glycan-based drug platform, not software integration

Low Howey risk; revenue model is pharmaceutical drug licensing, not token/investment scheme; primary product BXT-25 is a regulated therapeutic, not a security

Very High

Minimal GDPR/CCPA exposure; handles preclinical/clinical trial data under FDA/ICH frameworks, limited consumer PII, no large-scale data commercialization

Negligible antitrust risk; micro-cap clinical-stage company with no market share, no pricing power in current markets, and no M&A consolidation activity

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0% recurring revenue currently; 100% transactional/milestone-based future model via pharma licensing deals and eventual drug sales

Drug licensing royalties and potential milestone payments from pharma partners upon clinical and regulatory success

No commercial pricing yet; future pricing will follow orphan-drug/specialty pharma models, potentially $50K–$200K/treatment course, validated by clinical outcomes

Moderate-to-high potential pricing power if BXT-25 achieves FDA approval for stroke/hypoxia indications with no direct competitors

45.6% Gross Margin (Strong (40-60%))

No free-rider leakage problem; proprietary patented platform with no open-source analog; IP moat prevents unauthorized use

Revenue growth is highly sublinear to headcount; drug royalty/licensing model requires minimal additional staff at commercialization scale

Near-zero marginal cost of revenue at licensing stage; manufacturing scale-out costs borne by pharma partners, not BioxyTran

Not applicable; no franchise network

At 10x scale, CAC would be partnership-driven (BD spend ~$500K–$2M per deal); unit economics highly favorable if milestone payments exceed $10M per partnership

No network effects; pharmaceutical platform value is IP-driven, not user-base driven; clinical data accumulation provides marginal data-network benefit only

-322.4% Return on Assets (Negative equity)

Moderate resilience; acute neurological/stroke treatments are non-discretionary, but clinical funding and pharma partnership budgets contract in deep recessions

Large pharmaceutical and biotech companies as licensing partners and acquirers

Hospital systems and neurology centers as eventual end-use institutional customers post-commercialization

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated entirely to future-state R&D and clinical trials; no legacy operations or infrastructure maintenance capex to reallocate from

0001445815

BIXT